

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 28, 2024

LNCaP C4-2

RRID:CVCL_4782

Type: Cell Line

Proper Citation

(RRID:CVCL_4782)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4782

Proper Citation: (RRID:CVCL_4782)

Description: Cell line LNCaP C4-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Prostate carcinoma

Defining Citation: [PMID:8169003](#), [PMID:15162376](#), [PMID:26499105](#), [PMID:35502546](#)

Comments: Characteristics: Exhibits androgen-independent growth associated with skeletal metastasis, produces metastases when injected either subcutaneously or orthotopically in intact or castrated mice., Population: Caucasian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LNCaP C4-2

Synonyms: LNCaP-C4-2, LNCaP subline C4-2, C4-2, C42, Sp 2817

Cross References: ATCC:CRL-3314, BTO:BTO:0005672, cancercellines:CVCL_4782, ChEMBL-Cells:ChEMBL4295439, ChEMBL-Targets:ChEMBL4296460, Cosmic:1330914, GEO:GSM3145694, PubChem_Cell_line:CVCL_4782, Wikidata:Q54902814

ID: CVCL_4782

Hierarchy: CVCL_4783

Ratings and Alerts

No rating or validation information has been found for LNCaP C4-2.

No alerts have been found for LNCaP C4-2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 352 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Torres-Ayuso P, et al. (2024) PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer. *Cell chemical biology*, 31(2), 326.

Liu S, et al. (2024) UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. *Cell reports. Medicine*, 5(2), 101381.

Awad D, et al. (2024) Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity. *Cancer research*, 84(5), 703.

Khan N, et al. (2023) Drug Standardization through Pharmacognostic Approaches and Estimation of Anticancer Potential of Chamomile (*Matricaria chamomilla* L.) using Prostate-Cancer cell lines: An In-vitro Study. *Journal of Cancer*, 14(3), 490.

Shi SJ, et al. (2023) VIM⁺AS1 promotes proliferation and drives enzalutamide resistance in prostate cancer via IGF2BP2-mediated HMGCS1 mRNA stabilization. *International journal of oncology*, 62(3).

Blanc C, et al. (2023) The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer. *British journal of cancer*, 128(5), 918.

Gordon N, et al. (2023) PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. *bioRxiv : the preprint server for biology*.

Cui D, et al. (2023) Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation. *The Journal of clinical investigation*, 133(7).

Liu Y, et al. (2023) Endostatin 33 Peptide Is a Deintegrin $\alpha_6\beta_1$ Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. *Journal of clinical medicine*, 12(5).

Peng G, et al. (2023) Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance. *Oncoimmunology*, 12(1), 2173422.

Zhao Y, et al. (2023) Enhancer RNA promotes resistance to radiotherapy in bone-metastatic prostate cancer by m6A modification. *Theranostics*, 13(2), 596.

Tan X, et al. (2023) Identification and verification of an ALYREF-involved 5-methylcytosine based signature for stratification of prostate cancer patients and prediction of clinical outcome and response to therapies. *Discover. Oncology*, 14(1), 62.

Tao J, et al. (2023) Overexpression of DDX49 in prostate cancer is associated with poor prognosis. *BMC urology*, 23(1), 66.

Li Y, et al. (2023) Post-transcriptional modification of m6A methylase METTL3 regulates ERK-induced androgen-deprived treatment resistance prostate cancer. *Cell death & disease*, 14(4), 289.

Wells C, et al. (2023) SGC-CAMKK2-1: A Chemical Probe for CAMKK2. *Cells*, 12(2).

Salem O, et al. (2023) AR activates YAP/TAZ differentially in prostate cancer. *Life science alliance*, 6(9).

Rezaeian AH, et al. (2023) Pharmacological inhibition of the SKP2/p300 signaling axis restricts castration-resistant prostate cancer. *Neoplasia (New York, N.Y.)*, 38, 100890.

Xiao L, et al. (2023) Laser-activated nanoparticles for ultrasound/photoacoustic imaging-guided prostate cancer treatment. *Frontiers in bioengineering and biotechnology*, 11, 1141984.

Xie LY, et al. (2023) Development and validation of a tumor immune cell infiltration-related gene signature for recurrence prediction by weighted gene co-expression network analysis in prostate cancer. *Frontiers in genetics*, 14, 1067172.

Chianese U, et al. (2023) FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma. *Journal of translational medicine*, 21(1), 32.